WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202334
Description: PRLX 93936 is a structural analogue of erastin with potential antineoplastic activity. Erastin analogue PRLX 93936 appears to inhibit mitochondrial outer membrane protein VDACs (voltage-dependent anion channels) 2 and 3, resulting in an oxidative, non-apoptotic cell death. Erastin analogue PRLX 93936 exhibits greater lethality in cell lines harboring mutations in the GTPase protein oncogenes HRAS and KRAS or the serine-threonine protein kinase oncogene BRAF than in non-tumorigenic cell lines. VDACs 2 and 3 are up-regulated in a wide variety of tumor cell lines.
MedKoo Cat#: 202334
Chemical Formula: C21H24N4O2
Exact Mass: 364.1899
Molecular Weight: 364.449
Elemental Analysis: C, 69.21; H, 6.64; N, 15.37; O, 8.78
PRLX93936, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: PRLX93936; PRLX 93936; PRLX-93936; analogue of erastin.
IUPAC/Chemical Name: 3-(2-ethoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one
InChi Key: OBWOSMGNXYUDFB-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H24N4O2/c1-2-27-19-10-6-5-9-18(19)25-20(15-24-13-11-22-12-14-24)23-17-8-4-3-7-16(17)21(25)26/h3-10,22H,2,11-15H2,1H3
SMILES Code: O=C1N(C2=CC=CC=C2OCC)C(CN3CCNCC3)=NC4=C1C=CC=C4
The following data is based on the product molecular weight 364.449 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
PRLX 93936 is a product of extensive SAR work originating from a small molecule identified in a synthetic lethal screen against isogenic cell lines engineered to differentially express several genes including activated RasV12. Preclinical pharmacodynamic and toxicological studies, suggest that PRLX 93936 has great therapeutic potential and therefore, Prolexys initiated a Phase I clinical trial in August, 2007.
Note: Structure was from http://www.chemspider.com/Chemical-Structure.9734401.html (5/31/2016).